SDH缺陷型野生型GIST中胃泌素释放肽受体的体内表达及诊疗一体化潜力
本研究纳入12例组织学确诊的转移性SDH缺陷型野生型GIST患者,采用[68Ga]NeoB PET/CT评估胃泌素释放肽受体(GRPR)在病灶中的表达。8/12(66.7%)患者病灶显示强烈但异质性摄取,4例(33.3%)病灶摄取极少或无摄取。GRPR在病灶间及病灶内表达高度可变,NeoB在该病种中具有诊疗一体化应用潜力。
要点
- 多数转移性wtGIST患者病灶对[68Ga]NeoB呈强烈但异质性摄取。
- GRPR表达在病灶间及病灶内高度可变,需个体化评估。
- NeoB有潜力用于wtGIST诊疗一体化,[177Lu]NeoB治疗试验正在进行。
核心结论
- 多数wtGIST患者病灶显示强烈[68Ga]NeoB摄取,但摄取异质性提示GRPR表达高度可变。
- NeoB在缺乏有效标准治疗的wtGIST中具有诊疗一体化应用潜力。
研究设计与样本
- 本研究为小样本队列研究,纳入12例组织学确诊的转移性SDH缺陷型野生型GIST患者。
- 采用[68Ga]NeoB PET/CT进行病灶分割与摄取特征分析。
主要发现
- 8/12(66.7%)患者病灶显示强烈但异质性[68Ga]NeoB摄取,病灶内及病灶间摄取可变。
- 生理性摄取以胰腺、肝脏和脾脏最高。
- 4例(33.3%)患者肿瘤病灶摄取极少或无摄取。
关键数值与推荐
- 8/12(66.7%)患者病灶显示强烈[68Ga]NeoB摄取。
- 4例(33.3%)患者病灶摄取极少或无摄取。
- 生理性摄取最高位于胰腺、肝脏和脾脏。
临床怎么用
- [68Ga]NeoB PET/CT可用于评估wtGIST患者GRPR表达,辅助筛选适合未来靶向治疗试验的患者。
- 鉴于摄取异质性,需对病灶逐一评估,不宜仅凭整体判断。
局限性
- 本研究为小样本队列(12例),结论需更大样本验证。
- 摄取异质性可能影响患者选择与疗效预测的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Succinate dehydrogenase (SDH) deficient wild-type Gastrointestinal Stromal Tumours (wtGIST) are a rare GIST subtype with limited treatment options. Gallium-68 labelled Gastrin Releasing Peptide Receptor (GRPR) antagonist NeoB has shown promise in PET imaging for multiple primary malignancies. This investigation sought to assess the biodistribution of [68Ga]NeoB via PET/CT imaging in metastatic wtGIST patients and aimed to evaluate GRPR expression in lesions to determine the ligand's potential for patient selection in future therapeutic trials. RESULTS: Twelve patients with histologically confirmed metastatic wtGIST were enrolled. [68Ga]NeoB PET/CT imaging was conducted for lesion segmentation and analysis of uptake characteristics. 8 of 12 (66.7%) patients exhibited intense but heterogeneous [68Ga]NeoB uptake in lesions, with variable tracer uptake both within and between lesions. Physiological uptake was highest in the pancreas, liver, and spleen. Four patients (33.3%) displayed minimal or no uptake in tumour lesions. CONCLUSIONS: The majority of wtGIST patients in this small cohort show lesions with intense [68Ga]NeoB uptake. Heterogeneity of uptake indicates GRPR has highly variable inter- and intralesional expression. NeoB has potential for theranostic application in wtGIST, with limited effective standard of care treatments available. Ongoing trials are investigating the therapeutic use of [177Lu]NeoB in this setting. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Hulse DGE, Harper I, Tan F, et al. In vivo gastrin releasing peptide receptor expression in SDH deficient wild-type gastrointestinal stromal tumours (GIST): potential for theranostic applications. EJNMMI Res. 2025. PMID: 41118055. doi:10.1186/s13550-025-01299-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。